Medicus Pharma Q3 2024 Earnings Report

Medicus Pharma EPS Results

• Actual EPS: -$0.31
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Medicus Pharma Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Medicus Pharma Announcement Details

• Quarter: Q3 2024
• Date: 11/22/2024
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

Medicus Pharma (NASDAQ:MDCX), Inc., traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies. Its research and development efforts are centered on expanding a pipeline that includes additional oncology supportive care candidates as well as treatments aimed at acute neurological and critical conditions. The company partners with established contract manufacturers and distributors to facilitate efficient production and market access.

Medicus Pharma primarily serves the U.S. market through a network of specialty pharmacies and hospital systems and is evaluating opportunities for international distribution. Led by a management team with experience in specialty pharmaceuticals, regulatory affairs and commercial operations, the company remains focused on advancing its pipeline and delivering targeted support therapies for patients undergoing cancer treatment and acute care interventions.